Intended for healthcare professionals


Rofecoxib caused excess heart disease

BMJ 2005; 330 doi: (Published 27 January 2005) Cite this as: BMJ 2005;330:212
  1. Susan Mayor
  1. London

The COX 2 (cyclo-oxygenase-2) inhibitor rofecoxib (Vioxx) could have caused an estimated 88 000-140 000 excess cases of serious coronary heart disease in the United States since its launch in 1999, says a study published this week. The drug was withdrawn in September last year after being linked to increased cardiac deaths (BMJ 2004;329: 816).

The study analysed a cohort of all patients age 18-84 years receiving health care from a managed care organisation, Kaiser Permanente, in California, who were treated with …

View Full Text

Log in

Log in through your institution


* For online subscription